Edwards Lifesciences Corp Net Income
| EW Stock | USD 82.10 0.55 0.67% |
As of the 4th of February, Edwards Lifesciences shows the Mean Deviation of 0.9956, standard deviation of 1.22, and Variance of 1.48. Edwards Lifesciences Corp technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Edwards Lifesciences Corp risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Edwards Lifesciences Corp is priced favorably, providing market reflects its regular price of 82.1 per share. Given that Edwards Lifesciences has information ratio of (0.05), we urge you to verify Edwards Lifesciences Corp's prevailing market performance to make sure the company can sustain itself at a future point.
Edwards Lifesciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.4903 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 4.8 B | 5 B | |
| Net Income Applicable To Common Shares | 4.8 B | 5 B | |
| Net Income From Continuing Ops | 1.6 B | 883 M | |
| Net Income Per Share | 6.29 | 6.60 | |
| Net Income Per E B T | 2.43 | 2.55 |
Edwards | Net Income | Build AI portfolio with Edwards Stock |
The evolution of Net Income for Edwards Lifesciences Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Edwards Lifesciences compares to historical norms and industry peers.
Latest Edwards Lifesciences' Net Income Growth Pattern
Below is the plot of the Net Income of Edwards Lifesciences Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Edwards Lifesciences Corp financial statement analysis. It represents the amount of money remaining after all of Edwards Lifesciences Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Edwards Lifesciences' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.17 B | 10 Years Trend |
|
Net Income |
| Timeline |
Edwards Net Income Regression Statistics
| Arithmetic Mean | 1,443,371,735 | |
| Geometric Mean | 850,668,326 | |
| Coefficient Of Variation | 111.21 | |
| Mean Deviation | 1,155,807,156 | |
| Median | 811,100,000 | |
| Standard Deviation | 1,605,117,350 | |
| Sample Variance | 2576401.7T | |
| Range | 5B | |
| R-Value | 0.82 | |
| Mean Square Error | 885738.3T | |
| R-Squared | 0.68 | |
| Significance | 0.000049 | |
| Slope | 261,670,505 | |
| Total Sum of Squares | 41222427.3T |
Edwards Net Income History
Other Fundumenentals of Edwards Lifesciences Corp
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Edwards Lifesciences Net Income component correlations
Edwards Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Edwards Lifesciences is extremely important. It helps to project a fair market value of Edwards Stock properly, considering its historical fundamentals such as Net Income. Since Edwards Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edwards Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edwards Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Health Care Equipment & Supplies sector? Can Edwards capture new markets? Factors like these will boost the valuation of Edwards Lifesciences. Projected growth potential of Edwards fundamentally drives upward valuation adjustments. Valuation analysis balances hard financial data with qualitative growth assessments. While each Edwards Lifesciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Quarterly Earnings Growth (0.90) | Earnings Share 2.28 | Revenue Per Share | Quarterly Revenue Growth 0.147 | Return On Assets |
Investors evaluate Edwards Lifesciences Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edwards Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause Edwards Lifesciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Edwards Lifesciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edwards Lifesciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edwards Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.
Edwards Lifesciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Edwards Lifesciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Edwards Lifesciences.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Edwards Lifesciences on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Edwards Lifesciences Corp or generate 0.0% return on investment in Edwards Lifesciences over 90 days. Edwards Lifesciences is related to or competes with Becton Dickinson, Cardinal Health, Bruker, Argenx NV, Veeva Systems, Agilent Technologies, and STERIS Plc. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and ... More
Edwards Lifesciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Edwards Lifesciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Edwards Lifesciences Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 4.98 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 2.14 |
Edwards Lifesciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edwards Lifesciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Edwards Lifesciences' standard deviation. In reality, there are many statistical measures that can use Edwards Lifesciences historical prices to predict the future Edwards Lifesciences' volatility.| Risk Adjusted Performance | 0.0018 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.02) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Edwards Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Edwards Lifesciences February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0018 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 0.9956 | |||
| Coefficient Of Variation | (33,969) | |||
| Standard Deviation | 1.22 | |||
| Variance | 1.48 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 4.98 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 2.14 | |||
| Skewness | 0.1148 | |||
| Kurtosis | (0.59) |
Edwards Lifesciences Corp Backtested Returns
At this stage we consider Edwards Stock to be very steady. Edwards Lifesciences Corp secures Sharpe Ratio (or Efficiency) of close to zero, which denotes the company had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Edwards Lifesciences Corp, which you can use to evaluate the volatility of the firm. Please confirm Edwards Lifesciences' Mean Deviation of 0.9956, variance of 1.48, and Standard Deviation of 1.22 to check if the risk estimate we provide is consistent with the expected return of 5.0E-4%. The firm shows a Beta (market volatility) of 0.65, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edwards Lifesciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Edwards Lifesciences is expected to be smaller as well. Edwards Lifesciences Corp right now shows a risk of 1.23%. Please confirm Edwards Lifesciences Corp maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Edwards Lifesciences Corp will be following its price patterns.
Auto-correlation | 0.10 |
Insignificant predictability
Edwards Lifesciences Corp has insignificant predictability. Overlapping area represents the amount of predictability between Edwards Lifesciences time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Edwards Lifesciences Corp price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Edwards Lifesciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 2.44 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Edwards Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Edwards Lifesciences Corp reported net income of 4.17 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
Edwards Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edwards Lifesciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edwards Lifesciences could also be used in its relative valuation, which is a method of valuing Edwards Lifesciences by comparing valuation metrics of similar companies.Edwards Lifesciences is currently under evaluation in net income category among its peers.
Edwards Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Edwards Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Edwards Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Edwards Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in Edwards Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Edwards Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Edwards Lifesciences' value.| Shares | Norges Bank | 2025-06-30 | 7.4 M | Brown Advisory Holdings Inc | 2025-06-30 | 7.3 M | Ninety One Uk Limited | 2025-06-30 | 6.9 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 6.9 M | Millennium Management Llc | 2025-06-30 | 6.7 M | Northern Trust Corp | 2025-06-30 | 6.1 M | Deutsche Bank Ag | 2025-06-30 | 6 M | Wellcome Trust Ltd | 2025-06-30 | 4.8 M | Holocene Advisors, Lp | 2025-06-30 | 4.7 M | Vanguard Group Inc | 2025-06-30 | 70 M | Blackrock Inc | 2025-06-30 | 55.6 M |
Edwards Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0772 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 44.07 B | ||||
| Shares Outstanding | 580.3 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 90.00 % | ||||
| Number Of Shares Shorted | 7.92 M | ||||
| Price To Earning | 32.77 X | ||||
| Price To Book | 4.63 X | ||||
| Price To Sales | 8.19 X | ||||
| Revenue | 5.44 B | ||||
| Gross Profit | 4.6 B | ||||
| EBITDA | 1.72 B | ||||
| Net Income | 4.17 B | ||||
| Cash And Equivalents | 3.05 B | ||||
| Cash Per Share | 2.81 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.83 X | ||||
| Book Value Per Share | 17.57 X | ||||
| Cash Flow From Operations | 542.3 M | ||||
| Short Ratio | 2.38 X | ||||
| Earnings Per Share | 2.28 X | ||||
| Price To Earnings To Growth | 4.58 X | ||||
| Target Price | 97.02 | ||||
| Number Of Employees | 15.8 K | ||||
| Beta | 0.94 | ||||
| Market Capitalization | 48.2 B | ||||
| Total Asset | 13.06 B | ||||
| Retained Earnings | 13.17 B | ||||
| Working Capital | 4.78 B | ||||
| Current Asset | 2.05 B | ||||
| Current Liabilities | 476.2 M | ||||
| Net Asset | 13.06 B |
About Edwards Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edwards Lifesciences Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edwards Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edwards Lifesciences Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.